London, United Kingdom, 2 July 2026 — Algocyte® announced the launch of its Algocyte PROXIMA™ Mobile Health Station (MHS) at an event hosted at the Royal Society of Medicine (RSM) in London, where the company presented the current and future direction of its physics-informed AI technology designed for regular and remote health monitoring at home. For one day, the RSM was transformed by Algocyte's branding as the company unveiled Algocyte PROXIMA™.
Introducing Algocyte PROXIMA
Algocyte PROXIMA, designed and manufactured entirely in the UK, is an ultra-portable, versatile medical instrument intended for use by non-specialist healthcare providers, including nurses, GPs, pharmacists and care home staff, rather than laboratory technicians or phlebotomists. It requires only a small blood sample, comparable to that used for routine home glucose testing.
Algocyte was created by Oxford Immune Algorithmics, a company incubated by the University of Oxford, spun out from King's College London, with research from and studies conducted within the Cambridge and NHS ecosystems.
Launch event
The launch of Algocyte at the RSM featured a series of activities, including live demonstrations of the device in the Caversham Room and an immersive virtual reality training platform, three keynote talks delivered by internationally recognised professors in the Naim Dangoor Auditorium, and a company dinner held in the Society's Members' Dining Room.
The speakers included:
- Dr Kourosh Saeb-Parsy FRCS, Chief Medical Officer of Algocyte, Professor of Transplantation at the University of Cambridge and Honorary NHS Consultant associated also to Harvard's Massachusetts General Hospital, who presented the importance of regularly monitoring the immune system for precision medicine.
- Dr Jesper Tegnér, Director of Algocyte, Professor of Bioscience and AI at KAUST and Professor of Computational Medicine at the Karolinska Institute, who discussed the role of AI in medicine.
- Dr Hector Zenil FRSM, Founder and CEO of Algocyte and Associate Professor of Healthcare Engineering, also affiliated to the King's Institute for AI and the Francis Crick Institute who presented how disease signatures can be generated and monitored using Algocyte's technology.
The session was chaired by Dr Narsis Kiani, member of the Scientific Advisory Board of Algocyte, Senior Researcher from the Department of Oncology-Pathology of the Karolinska Institute and co-leader of the Algorithmic Dynamics Lab.
Virtual reality training
The immersive virtual reality platform demonstrated during the event enables healthcare professionals, including nurses, as well as patients, to learn how to operate Algocyte PROXIMA within a fully virtual environment that simulates the complete testing workflow using an Apple Vision Pro, representing a first for a medical instrument of its type.
Within the immersive experience, users can perform the entire testing procedure in real time, from preparing the device and collecting a finger-prick blood sample to operating the analyser, interacting with every component of the testing kit, pairing the instrument with a mobile phone, and reviewing the results on a virtual laptop. The platform provides a realistic, fully interactive training environment that mirrors the complete user experience without requiring a physical device or consumables.
Technology and engineering
Algocyte PROXIMA performs its blood analysis by combining two independent sensing technologies that keep its AI models grounded in physical measurements through a physics-informed approach. The instrument is operated via a mobile phone over Bluetooth, can function autonomously using a compact external power bank, and has been tested across multiple mobile connectivity environments, including Ethernet, WiFi, 5G and 4G hotspots, enabling deployment across a wide range of possible settings.
"We believe that the medical instruments of the 21st century should be as connected, portable and intuitive as the smartphones and devices we use at home," said Dr Hector Zenil, Founder and CEO of Algocyte, and Associate Professor of Healthcare Engineering at King's College London.
Its hybrid AI architecture leverages Algocyte PROXIMA's proprietary, patent-granted (US) and patent-pending methods, combining complementary neural network models, including convolutional and vision transformers, with Algocyte's quantum-inspired aggregation inference method, adding measurement redundancy and making it possible to produce the 13 biomarkers that constitute a full blood count (FBC) unlike any other portable device currently on the market.
"By grounding outputs in measurable physical parameters and cross-validating signals between sensors, the device's technological design constrains model behaviour and supports higher performance," said Dr Zenil.
From idea to market
Dr Zenil first conceived the idea for Algocyte while affiliated with the Karolinska Institute in Stockholm, Sweden, mentored under Prof Tegnér. Trained originally in pure mathematics, he later completed two PhDs in computer science, logic and epistemology at the Sorbonne/École Normale Supérieure and the University of Lille 1 in France. His research subsequently expanded into systems biology and computational medicine, beginning at the Behavioural Evolutionary Theory Lab at the University of Sheffield before joining the Unit of Computational Medicine at Karolinska Institute as an Assistant Professor.
While in Stockholm, Dr Zenil recognised an opportunity to bridge the gap between advances in computational biology and routine clinical practice. Building on research carried out at the Algorithmic Dynamics Lab, which he co-led with Dr Narsis Kiani at the Center for Molecular Medicine, he envisioned a technology capable of continuously monitoring the immune system to better understand, detect and ultimately help prevent the transition from health to disease.
After returning to the United Kingdom, Dr Zenil held successive research and academic appointments across each of the UK's Golden Triangle universities. He first joined the Department of Computer Science at the University of Oxford, before moving to the Department of Chemical Engineering and Biotechnology at the University of Cambridge, and subsequently to the School of Biomedical Engineering & Imaging Sciences at King's College London, where he is Associate Professor of Healthcare Engineering.
Regulatory progress
Building on research developed across Oxford, Cambridge and King's College London, and with Oxford and King's College London as shareholders, Dr Zenil assembled a multidisciplinary team that continues to lead the company today. Most of the core team has remained together for more than five years, bringing expertise spanning artificial intelligence, nanotechnology, biochemistry, mechatronics, immunology and even quantum computing without whom Algocyte wold not be possible. Their complementary technical backgrounds foster a highly interdisciplinary approach, united by a shared ambition to better understand the transition from health to disease and to develop technologies that enable earlier detection, continuous monitoring and more personalised healthcare. Among the milestones announced at the launch event held at the Royal Society of Medicine was the achievement of the UKCA mark for Algocyte PROXIMA as a UK IVD General Class medical instrument, marking readiness for clinical and commercial deployment.
This progress was further underpinned by the successful recent renewal and expansion of the company's certifications over the preceding months, including the extension of its quality management systems to manufacturing, alongside ISO 27001 (Information Security Management), ISO 13485 (Medical Devices — Quality Management Systems), Cyber Essentials Plus, and DSP requirements, reinforcing its commitment to quality, information security, governance and operational excellence.
Research and future
The company also announced that the next phase would progress regulatory pathways in additional jurisdictions, supported by pilot programmes in their early stages in the UK, Canada and the UAE, including initial positive feedback from laboratory operators and a Canadian rural community hub where the device is currently under evaluation. It further announced that it was preparing to launch its Series A fundraising round to support larger-scale commercialisation.
Algocyte will continue to develop and release future products in the Algocyte ecosystem and to test and validate its technology under an MHRA-approved licence granting access to the Clinical Practice Research Datalink (CPRD). The licence was granted following approval of the company's specific research programme and commercial novel intended use, enabling the further development and evaluation of its blood testing technology using longitudinal healthcare data, from which aggregated trends are analysed to derive comparative metrics and apply proprietary health scoring methodologies.
Editor's note
Dr Hector Zenil is a Fellow of the Royal Society of Medicine (RSM). The RSM does not endorse the product and acted solely as the venue for the event.
Event gallery
